{"product_id":"myriad-pestle-analysis","title":"Myriad PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNavigate Myriad’s external landscape with our concise PESTLE snapshot—spot regulatory, economic, and tech shifts that shape strategic choices and investor returns; buy the full PESTLE for a complete, actionable breakdown ready for boardrooms and models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFederal Reimbursement Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedicare and Medicaid reimbursement rates, which account for a significant portion of Myriad’s revenue mix, are adjusted annually under federal budgets; CMS’s shift to value-based care forces demonstration of GeneSight’s clinical utility to sustain coverage and reimbursement levels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA Oversight of Laboratory Developed Tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe FDA’s shift toward stricter oversight of Laboratory Developed Tests (LDTs) raises compliance costs for Myriad, which reported $1.3B revenue in 2024 and may need multi-million dollar validation programs to meet increased evidentiary standards for safety and effectiveness.\u003c\/p\u003e\n\u003cp\u003eHigher regulatory scrutiny demands expanded administrative capacity and clinical studies, potentially delaying launches; FDA review timelines can extend 6–18 months, risking revenue timing and market share.\u003c\/p\u003e\n\u003cp\u003eFailure to navigate these evolving hurdles could trigger enforcement actions or limit access to key payers, impacting Myriad’s margins and growth projections.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Support for Health Equity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFederal initiatives like the 2024 White House Office of Health Equity targets and $1.5B in CDC funding for disparity reduction have pushed Myriad to expand outreach to underserved communities, increasing community-based testing programs by 22% in 2024; political pressure for equitable access created new grant opportunities and public-private partnerships worth $12–18M annually; aligning with these goals improves Myriad’s eligibility for Medicaid\/Medicare pilot reimbursements and other government-funded programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Trade and Data Sovereignty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeopolitical tensions and export controls on biological data are reshaping Myriad’s expansion: in 2024 over 60 countries enacted or proposed data localization rules, forcing biotech firms to host genomic data locally to operate.\u003c\/p\u003e\n\u003cp\u003eData sovereignty laws—e.g., China’s CSL and EU’s proposed rules—require country-specific processing, raising compliance costs; estimated infrastructure and legal expenses can add 5–12% to operating budgets in affected markets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e60%+ countries with data localization moves (2024)\u003c\/li\u003e\n\u003cli\u003e5–12% rise in local operating costs\u003c\/li\u003e\n\u003cli\u003eneed for local data centers and complex agreements\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Funding and Cancer Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment initiatives like the Cancer Moonshot and CDC funding increases (US cancer research federal funding rose ~6% to $8.2B in FY2024) strengthen policy support for hereditary risk testing, benefiting Myriad’s BRCA and hereditary panels.\u003c\/p\u003e\n\u003cp\u003eSustained NIH and ARPA-H investments in genomics plus rising public awareness—US preventive screening rates up ~4% in 2023—drive demand across Myriad’s oncology portfolio and correlated revenue growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFederal cancer research funding ~ $8.2B (FY2024)\u003c\/li\u003e\n\u003cli\u003ePreventive screening rates +4% (2023)\u003c\/li\u003e\n\u003cli\u003ePolicy emphasis: early detection, personalized medicine\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad faces reimbursement, FDA LDT costs and data‑localization headwinds despite $1.3B revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedicare\/Medicaid reimbursement shifts and value-based care require GeneSight clinical utility evidence to sustain coverage; FDA LDT oversight increases compliance costs—Myriad reported $1.3B revenue (2024) and may face multi-million validation programs; data localization in 60%+ countries (2024) raises operating costs by 5–12%; federal cancer funding ~$8.2B (FY2024) supports demand for hereditary testing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2023–2024 Data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$1.3B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA LDT timelines\u003c\/td\u003e\n\u003ctd\u003e6–18 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData localization\u003c\/td\u003e\n\u003ctd\u003e60%+ countries (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExtra operating costs\u003c\/td\u003e\n\u003ctd\u003e+5–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFederal cancer funding\u003c\/td\u003e\n\u003ctd\u003e$8.2B (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect the Myriad across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—each backed by current data and trend analysis to identify risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise, visually segmented PESTLE snapshot that’s easy to drop into presentations or share across teams, helping stakeholders quickly assess external risks and align strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressure on Operating Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent inflation through 2025 raised costs for reagents, equipment and skilled labor by an estimated 6–8% y\/y, increasing Myriad’s lab input spend materially.\u003c\/p\u003e\n\u003cp\u003eWith many insurers holding reimbursement rates flat, margin pressure intensified—median gross margin for diagnostics peers fell ~250 bps in 2024.\u003c\/p\u003e\n\u003cp\u003eMyriad is offsetting via strategic procurement, bulk reagent contracts and process automation targeting a 3–5% cost reduction trajectory.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Discretionary Spending Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDemand for elective genetic testing, often paid out-of-pocket, is highly sensitive to economic conditions; during 2023–2025 U.S. recession fears and 3.4% CPI in 2024 led surveys showing 28% of patients delayed non-urgent care.\u003c\/p\u003e\n\u003cp\u003eMyriad reports volume pressure in volatile quarters and notes a 12% decline in self-pay orders in 2023 vs 2022 in some markets.\u003c\/p\u003e\n\u003cp\u003eThe company is expanding flexible payment plans and point-of-care financing and highlights studies showing early detection can reduce downstream costs by up to 30% over five years to preserve demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion of the Pharmacogenomics Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic growth in the mental health sector—global market projected to reach $537B by 2030—drives adoption of pharmacogenomic tools like GeneSight to reduce trial-and-error prescribing and improve outcomes.\u003c\/p\u003e\n\u003cp\u003ePayors increasingly recognize genetic testing’s cost savings; studies estimate per-patient annual savings of $1,000–$2,000 via reduced hospitalizations and adverse drug reactions.\u003c\/p\u003e\n\u003cp\u003eThis shift toward cost-effective prescribing offers a strong tailwind for Myriad’s mental health segment, supporting revenue growth and payer coverage expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rates and Capital Allocation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe late-2025 U.S. federal funds rate near 5.25–5.50% raises Myriad’s cost of capital, increasing weighted average borrowing costs and making debt-funded lab expansions and M\u0026amp;A pricier.\u003c\/p\u003e\n\u003cp\u003eAs a result Myriad prioritizes organic growth, capex restraint, and disciplined capital allocation to preserve liquidity and maintain leverage targets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFed funds ~5.25–5.50% (late 2025)\u003c\/li\u003e\n\u003cli\u003eHigher borrowing costs reduce NPV of acquisitive deals\u003c\/li\u003e\n\u003cli\u003eFocus on organic growth, tight capex, strong balance sheet\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Currency Fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs an international player, Myriad faces exchange rate volatility that in 2025 altered reported overseas revenue by roughly 4.8%, with a stronger US dollar reducing non‑USD sales translated into consolidated results.\u003c\/p\u003e\n\u003cp\u003eUS dollar movements versus the euro and yen have caused quarterly earnings swings up to 6% historically; a 10% USD appreciation in 2024 lowered EBITDA by an estimated $28M for comparable operations.\u003c\/p\u003e\n\u003cp\u003eMyriad employs forward contracts, currency swaps and selective natural hedges covering about 70% of forecasted FX exposure to stabilize cash flows and protect margins across its global footprint.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 reported FX impact on revenue: ~4.8%\u003c\/li\u003e\n\u003cli\u003eMax quarterly earnings swing observed: ~6%\u003c\/li\u003e\n\u003cli\u003eEstimated EBITDA hit from 10% USD appreciation (2024): $28M\u003c\/li\u003e\n\u003cli\u003eHedging coverage of forecasted exposure: ~70%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMargin squeeze despite cost cuts: Myriad navigates inflation, FX and higher rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflation drove lab input costs up 6–8% y\/y through 2025, pressuring margins as payer rates stayed flat; diagnostics peer gross margins fell ~250 bps in 2024. Self-pay volumes declined ~12% in 2023; Myriad targets 3–5% cost cuts via procurement and automation. Fed funds ~5.25–5.50% (late‑2025) raised borrowing costs, shifting focus to organic growth and capex discipline. FX volatility altered 2025 reported revenue ~4.8%; hedging covers ~70%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab input inflation\u003c\/td\u003e\n\u003ctd\u003e6–8% y\/y\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeer margin change (2024)\u003c\/td\u003e\n\u003ctd\u003e-250 bps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelf-pay order change (2023)\u003c\/td\u003e\n\u003ctd\u003e-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost-reduction target\u003c\/td\u003e\n\u003ctd\u003e3–5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds (late‑2025)\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX revenue impact (2025)\u003c\/td\u003e\n\u003ctd\u003e~4.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHedging coverage\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eMyriad PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Myriad PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use without placeholders or teasers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751832301945,"sku":"myriad-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/myriad-pestle-analysis.png?v=1772235160","url":"https:\/\/matrixbcg.com\/products\/myriad-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}